Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform
West Palm Beach, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform.
BioStem Technologies will utilize Terminal1’s integrated suite of shareholder intelligence, investor communications, and digital investor relations tools, giving the company a centralized platform to better understand its shareholder base, communicate with investors, and measure engagement across its investor ecosystem.
The addition of BioStem Technologies represents another step in Terminal1’s continued expansion as public companies increasingly look to consolidate traditionally fragmented investor relations functions into a single system.
“Public companies have historically relied on multiple vendors, disconnected data, and separate platforms to manage their investor ecosystem,” said Wesley De Souza, CDO, Terminal1. “Terminal1 was built to bring those functions together. We’re excited to welcome BioStem Technologies to the platform and continue demonstrating how shareholder data can be transformed into actionable intelligence.”
Through Terminal1, companies can access a growing suite of capabilities including:
- Shareholder Intelligence — Normalize and analyze shareholder and NOBO data to identify ownership trends, active buyers and sellers, shareholder concentration, geographic distribution, and changes over time.
- Investor Communications — Manage email and SMS communications from a centralized platform while tracking delivery, engagement, and subscriber activity.
- IR Website & Analytics — Manage a company’s investor-facing digital presence while measuring investor behavior, traffic sources, engagement, and conversions.
- Integrated Investor Data — Connect shareholder ownership, communications, and digital engagement to provide management teams with a more complete view of their investor ecosystem.
The platform is designed to provide CEOs, CFOs, investor relations teams, and other public-company executives with greater visibility into not only who owns their stock, but also how investors are interacting with the company.
“Adding BioStem Technologies is another important milestone for Terminal1,” added De Souza. “Our goal is straightforward: give public companies one system to understand their shareholders, communicate with the market, and measure what is actually driving investor engagement.”
Terminal1 continues to expand its public-company customer base as it builds out additional capabilities across shareholder intelligence, communications, analytics, and investor relations infrastructure.
About Terminal1
Terminal1 is an operating system built for public companies. The platform brings together shareholder intelligence, investor communications, IR website infrastructure, and investor analytics within one centralized system.Terminal1 helps public companies better understand their shareholders, engage their investor audience, and turn investor data into actionable insights.
For more information, visit www.terminal1.ai.
About BioStem Technologies, Inc.
(Nasdaq: BSEM): BioStem Technologies, Inc. is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.
BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the Association for Advancing Tissue and Biologics (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.
For more information, visit https://biostemtechnologies.com/.
Media Contact
Terminal1
Sally Pritchard
sally@terminal1.ai
